Recursion Pharmaceuticals (RXRX Quick Quote RXRX - Free Report) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing ...
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results